Perrigo News

Perrigo's Strategic Divestiture Prompts Buy Rating From Analyst Susan Anderson

TipRanksApr 26 08:07 ET

Perrigo Analyst Ratings

BenzingaApr 12 11:49 ET

Perrigo's Game-Changing Opill Gains Groundbreaking CVS Coverage: A Buy Rating Endorsement

TipRanksApr 8 07:25 ET

Perrigo Analyst Ratings

BenzingaApr 8 07:15 ET

Piper Sandler Remains a Buy on Perrigo Company (PRGO)

TipRanksApr 5 06:47 ET

Teva Upgraded at J.P. Morgan on Upcoming Catalysts

Seeking AlphaMar 8 10:21 ET

JP Morgan Maintains Overweight on Perrigo, Lowers Price Target to $41

BenzingaFeb 28 09:57 ET

Perrigo Analyst Ratings

BenzingaFeb 28 09:56 ET

Piper Sandler Remains a Buy on Perrigo Company (PRGO)

TipRanksJan 12 07:37 ET

Piper Sandler Issues a Buy Rating on Perrigo Company (PRGO)

TipRanksJan 3 07:51 ET

Piper Sandler Initiates Coverage On Perrigo With Overweight Rating, Announces Price Target of $37

BenzingaNov 17, 2023 05:07 ET

Perrigo Analyst Ratings

BenzingaNov 17, 2023 05:05 ET

Perrigo Company's Stock: A Buy Rating Amid Margin Improvements and Potential Upside From Opill Launch

TipRanksNov 8, 2023 07:43 ET

JP Morgan Maintains Overweight on Perrigo, Raises Price Target to $48

BenzingaAug 9, 2023 12:37 ET

Perrigo Analyst Ratings

BenzingaAug 9, 2023 12:36 ET

Canaccord Genuity Initiates Coverage On Perrigo With Buy Rating, Announces Price Target of $49

BenzingaMar 7, 2023 08:43 ET

Raymond James Adjusts Perrigo Price Target to $43 From $42, Maintains Outperform Rating

MT NewswiresMar 6, 2023 08:42 ET

Raymond James Reaffirms Their Buy Rating on Perrigo Company (PRGO)

TipRanksMar 5, 2023 07:51 ET

Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), FibroGen (FGEN) and Disc Medicine (IRON)

TipRanksFeb 28, 2023 06:46 ET

Raymond James Adjusts Price Target on Perrigo Company to $42 From $48, Maintains Outperform Rating

MT NewswiresNov 9, 2022 10:39 ET